Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discrepancy in ketamine IC50 values between these two studies might be explained by the concentration of agonist used (50 μM versus 1 mM glutamate), as higher agonist concentrations allow non-competitive antagonists, e.g. ketamine, to block more effectively due to a greater number of open channels”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lipton, 2006
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972 · cited 1×
“D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK293 and N1E-115 cell systems in a non-competitive manner.”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139 · cited 1×
“The NR2 family of NMDAR subunits contains a binding site for glutamate, the endogenous agonist, whereas the NR1 subunit binds glycin”
BackgroundVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658 · cited 1×
“kon Channel + MEM ↔ Channel–MEM (Blocked channel) (1)”
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Research works printed but not linked: 5
- Chen, H. -S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
- Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247–A238 (2005).
- Lipton, S. A., Rayudu, P. V., Choi, Y. -B., Sucher, N. J. & Chen, H. -S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73–82 (Elsevier, Amsterdam, 1998).
- Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
- Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
Cited by
Items 601–700 of 943
Mele, M., Alò, R., Avolio, E., & Canonaco, M. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0342-3 · Cited by 10
Novel 1,2,4-thiadiazoles with an NO-producing fragment
Serkov, I. V., Proshin, A. N., Petrova, L. N., & Бачурин, С. О. (2010) · Doklady Chemistry · doi:10.1134/s0012500810120013 · Cited by 10
Modern Approaches for the Discovery of Anti-Infectious Drugs for the Treatment of Neglected Diseases
Bellera, C. L., Sbaraglini, M. L., & Talevi, A. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180509151146 · Cited by 10
Fjelldal, M. F., Freyd, T., Evenseth, L. S. M., Sylte, I., Ring, A., & Paulsen, R. E. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.480 · Cited by 10
Prodrug Therapies for Infectious and Neurodegenerative Diseases
Marković, M., Deodhar, S., Machhi, J., Yeapuri, P., Saleh, M., Edagwa, B., Mosley, R. L., & Gendelman, H. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030518 · Cited by 12
“This atypical behavior allows memantine to attenuate excitotoxicity while preserving glutamatergic synaptic functions to offer clinical tolerability [44,45].”
BackgroundMetamodulation of presynaptic NMDA receptors: New perspectives for pharmacological interventions
Olivero, G., Grilli, M., Marchi, M., & Pittaluga, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109570 · Cited by 10
“HIV-1 can enter the brain soon after infection, leading to neurological alterations that contribute to the development of behavioral abnormalities, motor dysfunction, pain sensitization, and overt dementia (Kaul and Lipton, 2006; Siddiqui et al., 2022; Verma et al., 2010).”
BackgroundInfluentialMolecular simulation of drug-binding kinetics
Wong, C. F. (2014) · Molecular Simulation · doi:10.1080/08927022.2014.890722 · Cited by 10
“For example, the drug memantine for treating Alzheimer patients reduces toxicity by having fast off rate.[23] Memantine functions by blocking the N-methyl D aspartate receptor (NMDAR).”
BackgroundAn Enzymatic-HPLC Assay to Monitor Endogenous d-Serine Release from Neuronal Cultures
Radzishevsky, I. S., & Wolosker, H. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-331-8_19 · Cited by 10
Morin, L., Enderlin, J., Léger, P., Perrotte, G., Bonnin, P., Dupuis, N., Baud, O., Charriaut‐Marlangue, C., & Auvin, S. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.023 · Cited by 10
Amyotrophic Lateral Sclerosis: Current Therapeutic Perspectives
Kumar, V., Kashav, T., & Hassan, M. I. (2018) · Springer eBooks · doi:10.1007/978-981-13-0944-1_19 · Cited by 13
Arai, M., Imamura, O., Kondoh, N., Dateki, M., & Takishima, K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14803 · Cited by 10
Mechanisms of NMDA receptor inhibition by diarylamidine compounds
Dron, M. Y., Zhigulin, A. S., & Barygin, O. I. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14589 · Cited by 10
“For one of them, memantine (Lipton, 2006), inhibition of NMDA receptors is the main mechanism of its therapeutic action.”
BackgroundInfluence of retinal NMDA receptor activity during autoimmune optic neuritis
Bojcevski, J., Stojic, A., Hoffmann, D. B., Williams, S. K., Müller, A., Diem, R., & Fairless, R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14980 · Cited by 10
“The role of glutamate receptors in mediating neurodegeneration has been well described in many different pathophysiological conditions such as brain trauma, cerebral ischaemia and Alzheimer's disease (Lipton, 2006).”
BackgroundTorres‐Gómez, H., Lehmkuhl, K., Frehland, B., Daniliuc, C. G., Schepmann, D., Ehrhardt, C., & Wünsch, B. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.06.030 · Cited by 10
Jain, K. K. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-049-2_2 · Cited by 12
A new villain in neuronal death
Jones, S. (2020) · Science · doi:10.1126/science.abe2791 · Cited by 10
Aras, M. A., Jafari, N., Zonouz, A. M., & Hamishehkar, H. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139708 · Cited by 9
Identification and development of TRPM4 antagonists to counteract neuronal excitotoxicity
Binkle-Ladisch, L., Pironet, A., Zaliani, A., Alcouffe, C., Mensching, D., Haferkamp, U., Willing, A., Woo, M. S., Erdmann, A., Jessen, T., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111425 · Cited by 9
An iGlu Receptor Antagonist and Its Simultaneous Use with an Anticancer Drug for Cancer Therapy
Tan, S. Y., Ang, C. Y., Luo, Z. Y., Li, P., Nguyen, K. T., & Zhao, Y. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201406527 · Cited by 9
Li, Z., Wang‐Heaton, H., Cartwright, B. M., Makinwa, Y., Hilton, B., Musich, P. R., Shkriabai, N., Kvaratskhelia, M., Guan, S., Chen, Q., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202001636rrr · Cited by 11
Memantine-Related Psychotic Symptoms in a Patient With Bipolar Disorder
Canan, F., & Ataoğlu, A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09l05802gry · Cited by 9
E2-25K SUMOylation inhibits proteasome for cell death during cerebral ischemia/reperfusion
Jeong, E. I., Chung, H. W., Lee, W., Kim, S., Kim, H., Choi, S.-G., & Jung, Y. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.428 · Cited by 9
The ALS-Related σ1R E102Q Mutant Eludes Ligand Control and Exhibits Anomalous Response to Calcium
Rodríguez-Muñoz, M., Cortés‐Montero, E., Garzón, J., & Sánchez‐Blázquez, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197339 · Cited by 10
“The human σ1R E102Q mutant may deregulate the interactions of NMDARs with other signaling proteins, contributing to neurological disorders, including neurodegenerative diseases [39], and likely to alterations in motor coordination.”
BackgroundMemantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult
Ferrer‐Acosta, Y., Rodríguez-Massó, S. R., Pérez, D., Eterović, V. A., Ferchmin, P. A., & Martins, A. H. B. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105453 · Cited by 9
“Although the most recognized mechanism of action for memantine is the non-competitive antagonism of the NMDA receptor (Lipton, 2006; Johnson and Kotermanski, 2006; Song et al., 2018), other publications recognize its potential to inhibit the α7 nAChR as a pharmacological target for neurological…”
BackgroundRestorative effect of NitroSynapsin on synaptic plasticity in an animal model of depression
Tse, W. S., Pochwat, B., Szewczyk, B., Misztak, P., Bobula, B., Tokarski, K., Worch, R., Czarnota-Bojarska, M., Lipton, S. A., Zaręba-Kozioł, M., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109729 · Cited by 9
“…Reisberg et al., 2003; Lipton, 2004a, 2004b, 2004c, 2005, 2006, 2007a, 2007b, 2007c, 2022; Lipton and Heinemann, 2004; Lipton and Chen, 2004, 2005, 2006, 2007; Ding et al., 2016; Edinoff et al., 2021; Esch et al., 2002; Song et al., 2020; Witt et al., 2020; Schifitto et al., 2007; Zhao et al.,…”
Self-citationNovel binary compounds derived from 1,2,4-thiadiazole
Proshin, A. N., Serkov, I. V., & Бачурин, С. О. (2012) · Doklady Chemistry · doi:10.1134/s0012500812090017 · Cited by 9
Characterization of a Synthetic Steroid 24‐keto‐cholest‐5‐en‐3 β , 19‐diol as a Neuroprotectant
Yan, M., Liu, A., Zhou, S., Tang, L., Ou, Y., Yin, W. H., Chen, X., Su, X., Qiu, P., Huang, Y., et al. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12378 · Cited by 9
Victorino, D. B., Bederman, I. R., & Costa, A. C. S. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12816 · Cited by 9
“disorders, such as Parkinson’s disease, Huntington’s disease, stroke, chronic pain, migraine, amyotrophic lateral sclerosis, multiple sclerosis and autism spectrum disorder [4-11].”
BackgroundZhou, Z., Bai, J., Zhong, S., Zhang, R., Kang, K., Zhang, X., Xu, Y., Zhao, C., & Zhao, M. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5552623 · Cited by 10
“In view of this property, memantine, an NMDAR antagonist, has been developed for treating moderate-to-severe AD [67].”
BackgroundModular chemical probes for visualizing and tracking endogenous ion channels
McCarron, S. T., & Chambers, J. J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.033 · Cited by 9
“It is known that many neurodegenerative diseases such as Alzheimer's, Parkinson's, ALS, as well as acute disorders including stroke and epilepsy, share a final common pathway to neuronal injury due to overstimulation of glutamate receptors (Lipton, 2006).”
BackgroundNeuroprotective actions of 2,4-dinitrophenol: Friend or foe?
Ferreira, S. T., & Felice, F. G. D. (2007) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642008dn10400002 · Cited by 9
New lignans with neuroprotective activity from Adelostemma gracillimum
Zhang, J., Guo, S., Chan, K. W., Tong, E. P. S., Fu, G., Mu, Q., Ip, F. C. F., & Ip, N. Y. (2016) · Phytochemistry Letters · doi:10.1016/j.phytol.2016.02.011 · Cited by 9
“Memantine, which also exhibits neuroprotective effect (Lipton, 2006) was used as a positive control in this assay.”
BackgroundMethodKetogenic Approaches for the Treatment of Alzheimer’s Disease
Gabuzyan, R., Lee, C., & Nygaard, H. B. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240186 · Cited by 9
“Ketones have also been shown in preclinical studies to protect against glutamate excitotoxicity, which is the principal mechanism targeted by the widely approved AD drug memantine [25, 26].”
Kinetic Binding Mechanisms: Their Contribution to an Optimal Therapeutic Index
Swinney, D. C. (2011) · Wiley eBooks · doi:10.1002/9780470979129.ch19 · Cited by 8
Conjugation of aminoadamantanes by copper-catalyzed alkyne-azide 1,3-dipolar cycloaddition
Sokolov, V. B., Aksinenko, A. Y., Епишина, Т. А., & Горева, Т. В. (2018) · Russian Chemical Bulletin · doi:10.1007/s11172-018-2231-3 · Cited by 8
Wesierska, M., Svoboda, J., & Stuchlík, A. (2019) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2019.03.011 · Cited by 8
Yamaguchi, F., Hayakawa, S., Kawashima, S., Asakura, T., & Oishi, Y. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5370 · Cited by 11
Aras, M. A., & Zonouz, A. M. (2023) · Journal of Sulfur Chemistry · doi:10.1080/17415993.2023.2166348 · Cited by 8
Combating Oxidative/Nitrosative Stress with Electrophilic Counterattack Strategies
Satoh, T., Akhtar, M. W., & Lipton, S. A. (2013) · Springer eBooks · doi:10.1007/978-94-007-5787-5_10 · Cited by 8
Self-citationNon-competitive Inhibition of Nicotinic Acetylcholine Receptors by Ladybird Beetle Alkaloids
Leong, R. L., Xing, H., Braekman, J. C., & Kem, W. R. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1466-0 · Cited by 8
“Memantine, a use-dependent non-competitive antagonist (NCA) of NMDA type glutamate receptor channels, is currently administered to Alzheimer’s disease patients [2].”
BackgroundAteş‐Alagöz, Z., Sun, S., Wallach, J. V., & Adejare, A. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01124.x · Cited by 8
Horiuchi, H., Parajuli, B., Kawanokuchi, J., Jin, S., Mizuno, T., Takeuchi, H., & Suzumura, A. (2015) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12192 · Cited by 8
“As the proof of the involvement of excitotoxicity in AD pathogenesis, a N-methyl-D-aspartate (NMDA) receptor blocker, memantine, is clinically used for AD treatment.(12) We also reported that blockade of microglial glutamate release significantly improved memory impairment in a mouse model of AD.”
BackgroundSynthesis of adamantyl-containing phenylpiperidines
Shadrikova, V. A., Головин, Е. В., Shiryaev, V. A., Baimuratov, M. R., Rybakov, V. B., & Klimochkin, Y. N. (2015) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-015-1792-4 · Cited by 8
Castaneda, M. T., López, E. D., Touhami, A., Tovar, R., Ortega, M. R., & Rodriguez, J. M. (2015) · Neuroreport · doi:10.1097/wnr.0000000000000364 · Cited by 9
Ribić, R., Manček‐Keber, M., Chain, F. E., Sinnaeve, D., Martins, J. C., Jerala, R., Tomić, S., & Fehér, K. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c00029 · Cited by 8
Sharma, M., Mittal, A., Singh, A., Jainarayanan, A., Sharma, S. K., & Paliwal, S. (2020) · Biology Methods and Protocols · doi:10.1093/biomethods/bpaa013 · Cited by 8
Milestoning simulation of ligand dissociation from the glycogen synthase kinase 3β
Rathnayake, S., Narayan, B., Elber, R., & Wong, C. F. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26423 · Cited by 8
“For example, fast off rate plays an important role in reducing the toxicity of the drug memantine for treating Alzheimer's disease.(9) Memantine functions by blocking the N-methyl D aspartate receptor.”
BackgroundTouati, I., Abdalla, M., Ali, N. H., AlRuwaili, R., Alruwaili, M., Britel, M. R., & Maurady, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2217925 · Cited by 8
“…the release of glutamate, an endogenous NMDAR antagonist, while experimental evidence has shown that NMDAR antagonists might aid in protecting the cholinergic neurons found in the basal forebrain from the detrimental effects of A b peptides (Francis, 2005; Lipton, 2006; Nyakas et al., 2011).”
BackgroundNEUROLOGICAL CONSEQUENCES OF ABUSIVE USE OF ANABOLIC-ANDROGENIC STEROIDS
Gomides, L. F., de Oliveira, L. A., Mayers, N. A. J., Lacerda, F. B., Santos, J. P. B., Filho, B. B., Assunção, I. N., Cupertino, M. D. C., & Santana, M. G. (2024) · Tempus Actas de Saúde Coletiva · doi:10.18569/tempus.v13i1.2700 · Cited by 8
del Río‐Sancho, S., Serna-Jiménez, C. E., Calatayud-Pascual, M. A., Balaguer-Fernández, C., Femenía‐Font, A., Merino, V., & López‐Castellano, A. (2012) · Journal of Chemistry · doi:10.1155/2013/502652 · Cited by 8
Memantine treatment of juvenile rats with kaolin-induced hydrocephalus
Curzio, D. L. D., Nagra, G., Mao, X., & Bigio, M. R. D. (2018) · Brain Research · doi:10.1016/j.brainres.2018.04.001 · Cited by 8
Memory-Enhancing Drugs: A Molecular Perspective
Monti, B., & Contestabile, A. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709788452621 · Cited by 8
“This drug is a low-affinity reversible antagonist of the NMDA receptor that may counteract the excessive background activity of the receptor, occurring with age and development of dementia, without negatively affecting the normal receptor function required for cognition [51-53].”
BackgroundZou, Y., Sang, Y., Zheng, M., & Shi, B. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102685 · Cited by 7
“8 More recently, monoclonal antibodies targeting am- yloid-β (A β ) pathology, such as aducanumab and lecanemab, have been approved by the US Food and Drug Administration (FDA).”
Wang, Z., Xu, Z., Luo, Y., Peng, S., Song, H., Li, T., Zheng, J., Liu, N., Wu, S., Zhang, J., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1208274 · Cited by 7
“org proven by many studies to play an important role in AD and VaD pathology, and the glutamate antagonist memantine has been used in clinical practice to treat AD and VaD (Lipton, 2006; Reiner and Levitz, 2018).”
BackgroundShared interaction pathways of ligands targeting the ligand-binding pocket of nuclear receptors
Xiang, S., Wang, Z., Deng, Q., Tang, R., Wang, Q., Yu, Y., Hou, T., Hao, H., & Sun, H. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.102352 · Cited by 7
Lukomskaya, N. Y., Ватаев, С. И., Zhabko, E. P., & Magazanik, L. G. (2013) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-013-9877-y · Cited by 7
“Memantine blocks open ion channels in activated NMDA receptors, demonstrating voltage-dependent competition with magnesium ions [25, 31, 33, 40, 41].”
InfluentialAnchesi, I., Schepici, G., Chiricosta, L., Gugliandolo, A., Salamone, S., Caprioglio, D., Pollastro, F., & Mazzon, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119486 · Cited by 7
Wu, M., Xu, S., Mi, K., Yang, S., Xu, Y., Li, J., Chen, J., & Zhang, X. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1375843 · Cited by 7
“…activities, such as dendritic spine formation and brain maturation (Cull-Candy et al., 2001; Lai et al., 2014; Hardingham, 2019), and the use of selective NMDAR antagonists can cause various adverse reactions, such as cognitive impairment and hallucinations (Kemp and McKernan, 2002; Lipton, 2006).”
BackgroundSynthetic approaches to conjugation of aminoadamantanes and carbazoles
Sokolov, V. B., Aksinenko, A. Y., Епишина, Т. А., Горева, Т. В., & Бачурин, С. О. (2017) · Russian Chemical Bulletin · doi:10.1007/s11172-017-1988-0 · Cited by 7
Yepes, A. F., Ramírez, C. A., Rada, M. S., Cardona‐Galeano, W., Sierra, K., Osorio, E., González-Molina, L. A., & Posada‐Duque, R. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02886-y · Cited by 8
Drug Discoveries and Molecular Mechanism of Action
Swinney, D. C. (2015) · Wiley eBooks · doi:10.1002/9783527678433.ch2 · Cited by 7
Heusler, P., Tourette, A., & Cussac, D. (2015) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-015-1085-6 · Cited by 7
“Xenopus oocytes”
BackgroundWhy Alzheimer’s is a Disease of Memory: Synaptic Targeting by Pathogenic Aβ Oligomers (ADDLs)
Klein, W. L., Felice, F. G. D., Lacor, P. N., Lambert, M. P., & Zhao, W.-Q. (2008) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-540-76330-7_9 · Cited by 10
Zhang, Z., Yang, J., Zhang, L.-L., Chen, Z., Chen, J.-O., Cao, Y., Qu, M., Lin, X.-D., Ji, X.-M., & Han, Z. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.241461 · Cited by 8
“Memantine, a noncompetitive NMDAR antagonist, is widely used in the clinic (Vogels et al., 1997; Lipton, 2006).”
MethodBrain Ischemia and Reperfusion
Belayev, L., Lu, Y., & Bazan, N. G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00035-3 · Cited by 11
Zong, L., Chen, P., Shi, J., Chen, H., Lin, W., Ou, G., & Chen, X. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1695058 · Cited by 6
“Glutamate-mediated excitotoxicity is a common feature of many neuroinflammatory and neurodegenerative disorders, and targeting glutamate receptors with drugs such as memantine or riluzole could offer additional neuroprotection in viral encephalitis (Lipton, 2006).”
Nassrallah, W. B., Ramandi, D., Cheng, J., Oh, J. Y., Mackay, J. P., Sepers, M. D., Lau, D., Bading, H., & Raymond, L. A. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106360 · Cited by 6
Neuroprotective Effects of Noncanonical PAR1 Agonists on Cultured Neurons in Excitotoxicity
Babkina, I., Savinkova, I. G., Molchanova, T., Sidorova, M. V., Surin, A. M., & Горбачева, Л. Р. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021221 · Cited by 6
“These injurious processes include Ca 2+ overload of mitochondria, reactive oxygen and nitrogen species formation, activation of caspases and release of apoptosis-inducing factor [36,37].”
BackgroundZhou, Y., Yang, X., Hong, C., Guan, T., Xiao, P., Yang, Y., Zhang, C., & He, Z. (2025) · Biology · doi:10.3390/biology14020193 · Cited by 6
Su, J., He, Y., Li, M., Shen, Z., Ji, Q., Ren, Y., Fareed, M. S., & Wang, K. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108990 · Cited by 6
Lewis, B., Merlo, L. J., Greene, W. L., Welch, E., & Nixon, S. J. (2020) · Journal of Addictive Diseases · doi:10.1080/10550887.2020.1721404 · Cited by 6
“96] or interaction with time [F(2,40) 1⁄4 2.”
BackgroundLipton, S. A. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102267 · Cited by 6
Self-citationRivas‐Santisteban, R., Raïch, I., Aguinaga, D., Saura, C. A., Franco, R., & Navarro, G. (2023) · Cells · doi:10.3390/cells12020283 · Cited by 6
“Among the few approved medicines, memantine (marketed in the US as Namenda®) is a negative allosteric modulator of N-Methyl-D-Aspartate glutamate receptors (NMDARs) [2].”
BackgroundBurton, C. P., Chumin, E. J., Collins, A. Y., Persohn, S. A., Onos, K. D., Pandey, R. S., Quinney, S. K., & Territo, P. R. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1336026 · Cited by 7
“Memantine (Lipton, 2006), also known as Namenda, was one of the first approved drugs to treat AD and has a similar target to LEV: it works as an NMDA receptor antagonist aimed at quelling abnormal activity in the brain.”
BackgroundLadagu, A. D., Olopade, F. E., Chazot, P. L., Elufioye, T. O., Luong, T., Fuller, M., Halprin, E., Mckay, J., Ateş‐Alagöz, Z., Gilbert, T. T., et al. (2024) · BMC Neuroscience · doi:10.1186/s12868-024-00902-y · Cited by 6
“This model has proven to be valuable in investigating NMDA receptor (NMDAR) excitotoxicity and developing neuroprotective strategies [11, 83].”
BackgroundSong, Y., Chen, Y., Li, J., Sun, W., & Jin, F. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02821-3 · Cited by 6
Kim, K. K., Zaitsev, A. V., Vv, L., Zhabko, E. P., Ватаев, С. И., Lukomskaya, N. Y., & Magazanik, L. G. (2014) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-014-0008-1 · Cited by 6
Novel Spiro-Derivatives of 1,3-Thiazine Molecular Crystals: Structural and Thermodynamic Aspects
Perlovich, G. L., Proshin, A. N., Ol’khovich, M. V., Sharapova, A. V., & Lermontov, A. S. (2012) · Crystal Growth & Design · doi:10.1021/cg301511x · Cited by 6
Vasilev, D. S., Tumanova, N. L., Vv, L., Starshinova, L. A., Zhabko, E. P., Lukomskaya, N. Y., Zhuravin, I. A., & Magazanik, L. G. (2015) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-015-0106-8 · Cited by 6
Zeng, Z., Wang, D., Gaur, U., Rifang, L., Wang, H., & Zheng, W. (2017) · Oncotarget · doi:10.18632/oncotarget.18625 · Cited by 6
“Under pathological conditions, Ca2+ overload leads to the excessive Ca2+ influx through the receptor channels, triggering multiple intracellular catabolic processes, and thereby inducing an irreversible insult of neuronal cells [42].”
BackgroundO’Connell, A. B., Kuchel, T. R., Perumal, S. R., Sherwood, V., Neumann, D., Finnie, J. W., Hemsley, K. M., & Morton, A. J. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa053 · Cited by 6
Symptomatic treatments of N-methyl-D-aspartate receptor encephalitis
Lee, S. (2020) · encephalitis · doi:10.47936/encephalitis.2020.00045 · Cited by 6
“Because NMDAR mediates long-term potentiation of memory [2], memory loss is the early and key symptom in NMDAR encephalitis.”
BackgroundHuang, P., Zhou, Y., Li, X.-H., Zhang, Y., Cheng, H., Fu, J.-F., Liu, W. Q., Yue, S., & Luo, Z. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2507 · Cited by 7
“The activation of NMDAR subtypes is one of the main causes of glutamate excitatory toxicity, which mediates Ca 2+ -dependent cell death (13).”
Nakamura, T., Sharma, A., & Lipton, S. A. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00708 · Cited by 7
“Critically, NitroSynapsin has shown superior efficacy to memantine (the FDA-approved NMDA receptor antagonist previously developed by our group) in ameliorating disease-relevant phenotypes in preclinical models of AD, vascular dementia, and ASD [150 – 153] (reviewed in [10,154 – 156]).”
Self-citationIdentifying synergistic combinations of repurposed treatments for Alzheimer’s Disease
Ballard, C. G., Sultana, J., Doherty, P., Williams, G. H., & Corbett, A. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100329 · Cited by 7
Novel spiroderivatives of isothiourea of the 1,3-thiazine series as promising neuroprotectors
Proshin, A. N., Serkov, I. V., Petrova, L. N., & Бачурин, С. О. (2011) · Russian Chemical Bulletin · doi:10.1007/s11172-011-0377-3 · Cited by 5
Pashenko, A. E., Gaidai, A. V., Hryhoriev, N., Volovenko, O. B., Levandovskiy, I. A., Maksymenko, O., Volochnyuk, D. M., & Ryabukhin, S. V. (2023) · Organic Process Research & Development · doi:10.1021/acs.oprd.2c00305 · Cited by 5
Sasaki, T., Hisada, S., Kanki, H., Nunomura, K., Lin, B., Nishiyama, K., Kawano, T., Matsumura, S., & Mochizuki, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-77882-w · Cited by 5
Phillips, M. B., Povysheva, N. V., Neureiter, E. G., Nigam, A., Hartnett, K. A., Hell, J. W., Aizenman, E., & Johnson, J. W. (2026) · Science Advances · doi:10.1126/sciadv.aec3154 · Cited by 6
Closed Gateways — Can Neuroprotectants Shield the Retina in Glaucoma?
Velpandian, T. (2010) · Drugs in R&D · doi:10.1007/bf03259780 · Cited by 5
A compound CP-31398 suppresses excitotoxicity-induced neurodegeneration
Fujiwara, T., & Morimoto, K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.08.052 · Cited by 5
Novel hybrid compounds based on amino derivatives of 1,2,4-thiadiazole and docosahexaenoic acid
Serkov, I. V., Proshin, A. N., Petrova, L. N., Gretskaya, N. M., Безуглов, В. В., & Бачурин, С. О. (2012) · Doklady Chemistry · doi:10.1134/s0012500812110031 · Cited by 5
Paraplegia prevention by oral pretreatment with memantine in a rabbit model
Panthee, N., Ōno, M., Morota, T., Tanaka, T., Itoda, Y., Ikemura, M., Yamamoto, T., Suzuki, H., Saito, A., & Motomura, N. (2014) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.04.043 · Cited by 5
“Memantine is unique in that it preferentially blocks excessive (pathologic) NMDA receptor activity without disrupting normal (physiologic) function.(23) Memantine does this through its action as a low-affinity, but still highly selective, uncompetitive, open-channel blocker with a relatively rapid off rate from the ch…”
BackgroundSALM4 negatively regulates NMDA receptor function and fear memory consolidation
Lie, E., Yeo, Y., Lee, E., Shin, W., Kim, K., Han, K. A., Yang, E., Choi, T.-Y., Bae, M. H., Lee, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02656-3 · Cited by 5
Multifunctional Enzyme Inhibition for Neuroprotection - A Focus on MAO, NOS, and AChE Inhibitors
Joubert, J., Petzer, J. P., Prins, L. H. A., Repsold, B. P., & Malan, S. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50005-2 · Cited by 6
Protolytic properties of polyamine wasp toxin analogues studied by 13C NMR spectroscopy
Strømgaard, K., Piazzi, L., Olsen, C. A., Franzyk, H., & Jaroszewski, J. W. (2006) · Magnetic Resonance in Chemistry · doi:10.1002/mrc.1890 · Cited by 5
Neuroprotective Therapies for Multiple Sclerosis
Moreno, B., Villoslada, P., & Group Researcher (2012) · European Neurological Review · doi:10.17925/enr.2012.07.03.189 · Cited by 5
Cholesterol and Fat Metabolism in Alzheimer’s Disease
Taghibiglou, C., & Khalaj, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00009-x · Cited by 5
Bio-nano Interface and Its Potential Application in Alzheimer’s Disease
Pradhan, B., Jit, B. P., Maharana, S., Ramchandani, S., & Jena, M. (2021) · Springer eBooks · doi:10.1007/978-981-16-2516-9_12 · Cited by 5
Lo, Y. L., & Cheng, S. (2022) · Nutritional neurosciences · doi:10.1007/978-981-19-7327-7_7 · Cited by 5
Metadata
- Authors
- Lipton, S. A.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Lipton, Stuart A.
- ORCID
- Lipton, Stuart A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 160-170
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981238903
- Cited by
- 909
- References
- 98
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 32 · 2023: 31 · 2022: 40 · 2021: 41 · 2020: 51 · 2019: 42 · 2018: 36 · 2017: 40 · 2016: 48 · 2015: 51 · 2014: 47 · 2013: 48 · 2012: 52
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- memantine, NMDA receptor antagonists, neuroprotection, Alzheimer's disease, dementia, glutamate excitotoxicity, calcium influx, free radicals, adverse drug reactions, clinical trial failure, NMDA receptor overactivation
- MeSH terms
- Animals, Humans, Memantine, Neurotoxins, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.